Clinical Trials Logo

Clinical Trial Summary

To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.

Clinical Trial Description

Smoking remains the leading cause of preventable death and disability in the United States. Whereas smoking has declined significantly among individuals in the general population, it is clustered in populations of vulnerable individuals such as people living with HIV/AIDS (PLWH) in whom smoking prevalence rates and resulting comorbidity rates remain high. Medical advances in the treatment of HIV have resulted in substantial increases in life expectancy among PLWH and as a consequence PLWH smokers are now, more than ever, at heightened risk for tobacco-related illnesses and death. PLWH smokers engaged in treatment lose more years of life due to smoking now than to HIV disease. Although PLWH smokers engaged in HIV care typically see a medical provider every 4-6 months, smoking cessation treatment and referral is often not part of routine HIV care. While 94% of HIV treatment providers indicated that they would be willing to provide smoking cessation services to their patients, few have received training in how to provide smoking cessation services. With seven first line pharmacotherapies available for smoking cessation, development of algorithms to assist providers in selecting the most appropriate pharmacotherapy is an important but untested strategy to increase smoking cessation in PLWH. The purpose of this proposal is to conduct a mixed efficacy/effectiveness trial comparing an algorithm treatment with prescription cost off sets and quit line referral (AT) to an enhanced Treatment as Usual (quit line referral only; eTAU) group. Six hundred PLWH smokers will be recruited at the University of Alabama at Birmingham, University of Washington, and Fenway Health HIV clinics and will be randomized to receive AT or eTAU. All AT smokers will receive active treatment for twelve weeks regardless of stated motivation or intention to quit. eTAU smokers will be referred to quit line services and HIV providers may elect to treat smoking as part of standard of care. Participants will remain in the study for 12 months. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03670316
Study type Interventional
Source University of Alabama at Birmingham
Contact Karen L Cropsey, Psy.D.
Phone 2059757809
Status Not yet recruiting
Phase Phase 4
Start date July 1, 2019
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Completed NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT03477279 - Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi N/A
Recruiting NCT03483857 - Peer Navigation to Improve Engagement in Care for HIV-Positive Men Who Have Sex With Men in Ehlanzeni, South Africa N/A
Not yet recruiting NCT03487796 - MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South N/A
Not yet recruiting NCT03649607 - Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black N/A
Not yet recruiting NCT03618862 - Study of the Effects of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent Provirus
Recruiting NCT02887209 - A Pragmatic Pilot Study of Cognitive Behavioural Therapy for Insomnia Among People Living With HIV N/A
Recruiting NCT03059121 - The Cleveland Cardiometabolic Cohort
Recruiting NCT02929069 - A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk N/A
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Recruiting NCT02924389 - Dolutegravir in Reservoirs N/A
Recruiting NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Active, not recruiting NCT02856269 - Zinc Supplementation and Cardiovascular Risk in HIV N/A
Completed NCT02869776 - Integrating HCV and HIV Screening During the Era of HIV Antigen Testing N/A
Not yet recruiting NCT02844634 - Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM Phase 4
Completed NCT02931422 - Financial Incentives to Increase Pediatric HIV Testing Pilot Study (FIT-Pilot) N/A
Recruiting NCT02556957 - CHWs, mHealth, and Combination HIV Prevention N/A